The first Ebola vaccine to be tested on humans, developed by GlaxoSmithKline and the US National Institutes of Health, has shown promising results in early trials, paving the way for it to be tested on healthcare workers in west Africa in the new year. Fiona Symon spoke to Andrew Ward about the potential of the vaccine to address the Ebola crisis

iTunes Stitcher audioBoom SoundCloud Overcast RSS

Copyright The Financial Times Limited 2017. All rights reserved.

Follow the topics related to this show

Comments have not been enabled for this podcast.